Information Provided By: 
Fly News Breaks for September 26, 2016
GWPH
Sep 26, 2016 | 09:28 EDT
Piper Jaffray analyst Joshua Schimmer says that with three out of three pivotal trials now positive, GW Pharmaceuticals is "increasingly well positioned" for FDA submission next year. Epidiolex continues to demonstrate a "robust and consistent effect in a drug refractory population," Schimmer tells investors in a research note after GW announced top-line data from the second Phase 3 study in Lennox-Gastaut Syndrome. He reiterates an Overweight rating on the shares with a $147 price target.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
